Monday, April 04, 2005

Two sides of the same coin?

Ranbaxy Receives FDA Approval To Market A Generic Alternative To Macrobid
Total annual market sales for Nitrofurantoin Monohydrate/Macrocrystals Capsules were $80.0 million (IMS - MAT: December 2004).


“We are delighted to receive approval from the U.S. FDA to market this product to add to our ever growing generic product portfolio. Our plans are to bring this product to the market as quickly as possible during the month of April,” according to Jim Meehan, Vice President of Sales and Marketing for RPI, USA.

Schering drug Asmanex, finally gets FDA approval
Once hailed as a billion-dollar-a-year blockbuster, the drug is now seen by analysts as a more moderate seller.

“It would have been a big deal if they would have gotten approval four years ago,” said Sena Lund, an analyst with Cathay Financial LLC. Still, Lund called the approval a “positive” for the drug maker, and forecasted peak annual sales to reach as much as $300 million.
Now, while I am not necessarily a big fan of big drug companies, this seems to be a classic case of a "blockbuster" drug that fizzled because the FDA messed around and didn't approve. Not to mention that this is 7 years of patent time that has expired without any sales. That much close to generic competition.